Serious adverse events participant and study investigator reported · people with chronic gout
Skim milk enriched with GMP/G600 showed no clear difference in serious adverse events participant and study investigator reported compared with skim milk & lactose powder (low certainty).
1 finding from 1 review
Mean pain intensity (Numeric Rating Scale 0–10) · lateral elbow pain
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Patients with shoulder pain
1 finding from 1 review
Participant‐assessed success 50% improvement on numerical rating 0 to 10 scale for pain) · Patients with shoulder pain
It is very uncertain whether ultrasound‐guided injection changes participant‐assessed success 50% improvement on numerical rating 0… compared with non‐image‐guided injection (very low certainty).
1 finding from 1 review
Intervention not reported
Participation restrictions 100 mm return to usual work activities VAS (higher score reflects better outcome) · people with non‐neurological conditions1
1 finding from 1 review
Intervention not reported
Participation restrictions · people with neurological conditions1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement: American College of Rheumatology 20% improvement criteria (ACR20) · patients with rheumatoid arthritis
Celecoxib probably leads to higher clinical improvement: American College of Rheumatology 20%… compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement: American College of Rheumatology 20% improvement criteria (ACR20) · patients with rheumatoid arthritis
Celecoxib showed no clear difference in clinical improvement: American College of Rheumatology 20%… compared with traditional NSAIDs (moderate certainty).
1 finding from 1 review
ACR 50% improvement · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate probably leads to higher clinical improvement American College of Rheumatology 50%… compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Intervention not reported
ACR 50 American College of Rheumatology improvement criteria · patients with rheumatoid arthritis
The intervention probably leads to higher ACR 50 American College of Rheumatology improvement criteria (moderate certainty).
1 finding from 1 review
Pain ‐ change from baseline to 24 to 72 hours Assessed on numerical rating scale (0 = no pain; 10 = extreme pain) · acute gout
1 finding from 1 review
Intervention not reported
ACR50 American College of Rheumatology 50% improvement criteria · participants with rheumatoid arthritis and with a partial response to DMARDs
The intervention probably leads to higher ACR50 American College of Rheumatology 50% improvement criteria (moderate certainty).
1 finding from 1 review
Intervention not reported
Outcome: ACR50 ‐ American College of Rheumatology Improvement Criteria · participants with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
ACR50 American College of Rheumatology improvement criteria · participants with rheumatoid arthritis and with partial response to MTX
The intervention probably leads to higher ACR50 American College of Rheumatology improvement criteria (moderate certainty).
1 finding from 1 review
Muscle strength · patients with fibromyalgia
1 finding from 1 review
Arthroplasty instability ‐ inferred from roentgen stereophotogrammetric analysis (Available data analysis) · Patients with osteoarthritis and other non‐traumatic diseases
Uncemented fixation with and without hydroxyapatite probably leads to lower arthroplasty instability ‐ inferred from roentgen… compared with cemented fixation (moderate certainty).
1 finding from 1 review
Serum uric acid <6.0 mg/dL at final visit · patients with chronic cout
Febuxostat 120 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).
1 finding from 1 review
Serum uric acid <6.0 mg/dL at final visit · people with chronic gout
Febuxostat 40 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).
1 finding from 1 review
Serum uric acid <6.0 mg/dL at final visit · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).
1 finding from 1 review
Serum uric acid <6.0 mg/dL at final visit · people with chronic gout
Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (low certainty).
1 finding from 1 review